Institutional conflict of interest: attempting to crack the deferiprone mystery
A recent study by Olivieri et al, published in PLOS ONE, reports that between 2009 and 2015 a third of patients with thalassaemia in Canada’s largest hospital were switched from first-line licensed drugs to regimens of deferiprone, an unlicensed drug of unproven safety and efficacy. Based on retrosp...
Main Author: | |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
BMJ Publ.
2021
|
In: |
Journal of medical ethics
Year: 2021, Volume: 47, Issue: 8, Pages: 531-538 |
Online Access: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |